Skip to main content

Advertisement

SpringerLink
Log in

The Therapeutic Management of Bleeding and Thrombotic Disorders Complicating CNS Malignancies

  • Neuro-oncology (GJ Lesser, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Patients with central nervous system (CNS) malignancies have a substantial risk for developing both thrombotic and bleeding disorders. The risk of venous thromboembolism (VTE) is substantially higher in these patients, both in the perioperative period and throughout their disease course. Patients with CNS malignancy harbor a latent hypercoagulability, which predisposes to VTE, as do postoperative immobility, hemiparesis, and other factors. The management of VTE in these patients is complex, given the significant morbidity and mortality associated with intratumoral hemorrhage. In the past, the perceived risk of intracranial hemorrhage limited the use of anticoagulation for the management of VTE with many favoring nonpharmacologic methods for prophylaxis and treatment. Inferior vena cava (IVC) filters have since lost favor at many centers given significant complications, which appear to be more frequent in patients with CNS malignancy. Recent studies have demonstrated safe and efficacious use of anticoagulation in these patients with a low incidence of intracranial hemorrhage. Treatment of established VTE is now recommended in this population with many centers favoring low-molecular-weight heparin (LMWH) versus oral warfarin for short- or long-term treatment. We advocate a multimodality approach utilizing compression stockings, intermittent compression devices, and heparin in the perioperative setting as the best proven method to reduce the risk of VTE. In the absence of a strict contraindication to systemic anticoagulation, such as previous intracranial hemorrhage or profound thrombocytopenia, we recommend LMWH in patients with newly diagnosed VTE and a CNS malignancy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Dietcher SR. Cancer and thrombosis: mechanisms and treatment. J Thromb Thrombolysis. 2003;16:21–31.

    Article  Google Scholar 

  2. Sorenson HT, Mellemkjaer L, Olsen JH, Baron JH. Prognosis of cancers associated with venous thromboembolism. N Eng J Med. 2000;343:1846–50.

    Article  Google Scholar 

  3. Levi AD, Wallace MC, Bernstein M, Walters BC. Venous thromboembolism after brain tumor surgery: a retrospective review. Neurosurgery. 1991;28:859–63.

    Article  PubMed  CAS  Google Scholar 

  4. Sawaya R, Zuccarello M, Elkalliny M, Nishiyama H. Postoperative venous thromboembolism and brain tumors: part I. J Neurooncol. 1992;14:119–25.

    PubMed  CAS  Google Scholar 

  5. Semrad TJ, O’Donnell R, Wun T, Chew H, Harvey D, Zhou H, et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg. 2007;106:601–8.

    Article  PubMed  Google Scholar 

  6. Cage TA, Lamborn KR, Ware ML, Frankfurt A, Chakalain L, Berger MS, et al. Adjuvant enoxaparin therapy may decrease the incidence of postoperative thrombotic events though does not increase the incidence of postoperative hemorrhage in patients with meningiomas. J Neurooncol. 2009;93(1):151–6.

    Article  PubMed  CAS  Google Scholar 

  7. Brandes A, Scelzi E, Salmistararo G, et al. Incidence of risk of thromboembolism during treatment of high-grade gliomas: a prospective study. Eur J Cancer. 1997;33:1592–6.

    Article  PubMed  CAS  Google Scholar 

  8. Simanek R, Vormittag R, Hassler M, Roessler K, Schwarz M, Zielinski C, et al. Venous thromboembolism and survival in patients with high-grade glioma. Neuro Oncol. 2007;9:89–95.

    Article  PubMed  Google Scholar 

  9. Streiff MB, Segal J, Grossman SA, Kickler TS, Weir EG. ABO blood group is a potent risk factor for venous thromboembolism in patients with malignant gliomas. Cancer. 2004;100:1717–23.

    Article  PubMed  Google Scholar 

  10. Rodas TA, Fenstermaker RA, McKeever PE, Blaivas M, Dickinson LD, Papadopoulos SM, et al. Correlation of intraluminal thrombosis in brain tumor vessels with postoperative thrombotic complications: a preliminary report. J Neurosurg. 1998;89:200–5.

    Article  PubMed  CAS  Google Scholar 

  11. Ruff RL, Posner JB. Incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann Neurol. 1983;13:334–6.

    Article  PubMed  CAS  Google Scholar 

  12. Thoron L, DeAngelis LM. Thromboembolic disease in primary CNS lymphoma. Proc Am Soc Clin Oncol. 10:A3811.

  13. Komrokji RS, Uppal NP, Khorana AA, Lyman GH, Kaplan KL, Fisher RI, et al. Venous thromboembolism in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2006;47(6):1029–33.

    Article  PubMed  Google Scholar 

  14. Ay C, Dunkler D, Simanek R, et al. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2011;29:2099–103.

    Article  PubMed  Google Scholar 

  15. Milsom CC, Yu JL, Mackman N, et al. Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis. Cancer Res. 2008;68:100068–76.

    Google Scholar 

  16. Rong Y, Belozerov VE. Tucker-Burden, et al. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/Activator Protein-1 transcriptional activity. Cancer Res. 2009;69:2540–3549.

    Article  PubMed  CAS  Google Scholar 

  17. Ay C, Vormittag R, Dunkler D, et al. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2009;27:4124–9.

    Article  PubMed  CAS  Google Scholar 

  18. Hoke M, Dieckmann K, Koppensteiner, et al. Prognostic value of plasma D-dimer levels in patients with glioblastoma multiforme – Result from a pilot study. Wien Klin Wochenschr. 2011;123:199–203.

    Article  PubMed  CAS  Google Scholar 

  19. Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902–7.

    Article  PubMed  CAS  Google Scholar 

  20. Beck-Razi N, Kuzmin A, Koren D, et al. Asymptomatic deep vein thrombosis in advanced cancer patients: the value of venous sonography. J Clin Ultrasound. 2010;38(5):232–7.

    PubMed  Google Scholar 

  21. Segal JB, Eng J, Tamariz LJ, Bass EB. Review of evidence on diagnosis of deep venous thrombosis and pulmonary embolism. Ann Fam Med. 2007;5(1):63–73.

    Article  PubMed  Google Scholar 

  22. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007;5(4):692–9.

    Article  PubMed  CAS  Google Scholar 

  23. Jenkins EO, Schiff D, Mackman N, Key NS. Venous thromboembolism in malignant gliomas. J Thromb Haemostatis. 2009;8:221–7. This clinically relevant review article provides an excellent update on the current status of venous thromboembolism in patients with malignant gliomas, including updates on available data investigating the use of anticoagulation inpatients on bevacizumab.

    Article  Google Scholar 

  24. Levin JM, Shiff D, Loeffler JS, et al. Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology. 1993;43:1111–4.

    Article  PubMed  CAS  Google Scholar 

  25. Wen PY, Shiff D, Kesari S, Drappatz J, et al. Medical management of patients with brain tumors. J Neurooncol. 2006;80:313–32.

    Article  PubMed  CAS  Google Scholar 

  26. Pan E, Tsai JS, Mitchell SB. Retrospective study of venous thromboembolic and intracerebral hemorrhagic events in glioblastoma patients. Anticancer Res. 2009;29:4309–14.

    PubMed  Google Scholar 

  27. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology Guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25:5490–505.

    Article  PubMed  CAS  Google Scholar 

  28. Joels CS, Sing RF, Heniford BT. Complications of inferior vena cava filters. Am Surg. 2003;69(8):654–9.

    PubMed  Google Scholar 

  29. Schiff D, DeAngelis LM. Therapy of venous thromboembolism in patients with brain metastases. Cancer. 1994;73(2):493–8.

    Article  PubMed  CAS  Google Scholar 

  30. Perry JR, Julian JA, Laperriere NJ, et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost. 2010;8(9):1959–65. Interesting study terminated prematurely possibly suggesting increased intracranial bleeding with LMWH thromboprophylaxis in patients with malignant gliomas.

    Article  PubMed  CAS  Google Scholar 

  31. Perry SL, Bohlin C, Reardon DA, et al. Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. J Neurooncol. 2009;95:129. Interesting pilot study reporting the safe use of LMWH for primary thromboprophylaxis in patients with malignant gliomas.

    Article  PubMed  CAS  Google Scholar 

  32. Schmidt F, Faul C, Dichgans J, Weller M. Low molecular weight heparin for deep vein thrombosis in glioma patients. J Neurol. 2002;249:1409.

    Article  PubMed  CAS  Google Scholar 

  33. Dickson LD, Miller LD, Patel CP, Gupta SK. Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors. Neurosurgery. 1998;43:1074.

    Article  Google Scholar 

  34. Agnelli G, Piovella F, Buoncristiani P, et al. Enoxaparin plus compression stockings compared with compression stockings alone in prevention of venous thromboembolism after elective neurosurgery. N Eng J Med. 1998;339:80.

    Article  CAS  Google Scholar 

  35. Monreal M, Zacharski L, Jimenez JA, et al. Fixed dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study. J Thromb Haemost. 2004;2:1311.

    Article  PubMed  CAS  Google Scholar 

  36. Trujillo-Santos J, Nieto JA, Ruiz-Gamietea A, et al. Bleeding complications associated with anticoagulant therapy in patients with cancer. Thromb Res. 2010;125:S58–61.

    Article  PubMed  Google Scholar 

  37. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Eng J Med. 2003;349:136–53.

    Google Scholar 

  38. Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008;300:2277–85.

    Article  PubMed  CAS  Google Scholar 

  39. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27.(28):4733–40. This article was pivotal along with other data in the approval of bevacizumab for the treatment of recurrent glioblastoma and includes important information regarding hemorrhage risk in this population.

    Article  PubMed  CAS  Google Scholar 

  40. Besse B, Lasserre SF, Compton P, Huang J, Augustus S, Rohr UP. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res. 2010;16(1):269–78. Important retrospective analyses that supports the safe use of bevacizumab in select patients with CNS metastases.

    Article  PubMed  CAS  Google Scholar 

  41. Nghiemphu PL, Green RM, Pope WB, et al. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol. 2008;10:355.

    Article  PubMed  Google Scholar 

  42. Goli KJ, Desjardins A, Herndon JE, et al. Phase II trial of bevacizumab and irinotecan in the treatment of malignant gliomas. ASCO annual meeting proceedings part I. J Clin Oncol. 2007;25:185.

    Google Scholar 

  43. Socinski MA, Langer CJ, Huang JE, et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol. 2009;27(31):5255–61.

    Article  PubMed  CAS  Google Scholar 

  44. Ngheimphu PL, Green RM, Pope WB, et al. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol. 2008;355-60.

  45. Bartolomeo J, Norden AD, Drappatz J, et al. Safety of concurrent bevacizumab therapy and anticoagulation in high grade glioma patients (abstract #2043). J Clin Oncol. 2010;28:190s.

    Article  Google Scholar 

  46. Cerrato D, Ariano C, Fiacchino F. Deep vein thrombosis and low-dose heparin prophylaxis in neurosurgical patients. J Neurosurg. 1978;49:378–81.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Wake Forest Baptist Health, Medical Center Boulevard, Winston Salem, Box 2409, NC, 27157, USA

    Roy E. Strowd III MD, Mary Ann Knovich MD & Glenn J. Lesser MD

Authors
  1. Roy E. Strowd III MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mary Ann Knovich MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Glenn J. Lesser MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roy E. Strowd III MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Strowd, R.E., Knovich, M.A. & Lesser, G.J. The Therapeutic Management of Bleeding and Thrombotic Disorders Complicating CNS Malignancies. Curr. Treat. Options in Oncol. 13, 451–464 (2012). https://doi.org/10.1007/s11864-012-0207-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-012-0207-3

Keywords

Search

Navigation